Manufacturer: Crowx Labs
Pharmaceutical name: Tirzepatide
Pack: 1 vial (5 mg)
Tirzepatide is an agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, approved by the FDA for the management of type 2 diabetes mellitus. It is essential to highlight that tirzepatide is not authorized for use in type-1 diabetes mellitus patients and has not undergone studies in individuals with pancreatitis. This medication significantly enhances glycemic control in those with type 2 diabetes while also promoting substantial weight loss.
Tirzepatide may also be prescribed off-label for obesity treatment. It is currently utilized as a second-line therapy for diabetes, similar to GLP-1 medications like semaglutide. This treatment is administered as a subcutaneous injection on a weekly basis, with doses gradually increased.
Tirzepatide is a synthetic peptide functioning as a dual agonist for gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptors. It consists of 39 amino acids and is an analog of gastric inhibitory polypeptide. Functionally, it promotes insulin secretion from the pancreas and results in reduced hyperglycemia. Furthermore, tirzepatide boosts adiponectin levels. Its dual action provides a more pronounced decrease in hyperglycemia compared to GLP-1 agonists alone and curbs the user's appetite.
Pharmacokinetics:
Absorption: Tirzepatide has a bioavailability of roughly 80%, with peak serum levels reached in a timeframe of 8 to 72 hours.
Distribution: The average apparent steady-state volume of distribution (Vd) for tirzepatide is about 10.3 L, and it is highly bound to plasma albumin (99%).
Metabolism: Following injection, the peptide structure experiences proteolytic cleavage, while the C20 fatty diacid goes through beta-oxidation and amide hydrolysis.
Excretion: With a half-life of 5 days, tirzepatide allows for a once-weekly dosing schedule and is eliminated via urine and feces as metabolites.